Medscape MedBrief
Twice-daily bictegravir/emtricitabine/tenofovir alafenamide resulted in high sustained viral suppression rates over 48 weeks in patients with HIV infection receiving rifampicin-based treatment for TB. The regimen was safe and well tolerated, with no discontinuations or drug switches due to adverse events.
Read the full MedBrief here.
* The MedBrief was created using several editorial tools, including AI, as part of the process. Human editors reviewed the content before publication.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #2, 18 January 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Medscape
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.